Motif BioSciences, Inc.
Motif BioSciences, Inc. works with a variety of human Founder Populations to accelerate discovery of genetic variation that is involved in disease pathways. Motif’s approach stacks the odds for making novel discoveries by applying a proprietary analytical approach to these populations.
With low pharmaceutical productivity and substantial drug patent expiration, Motif’s business aims are to aid pharmaceutical and diagnostic companies by:
- developing new pathways for target discovery for drug development;
- partnering to develop Motif’s genetic information into disease risk assessment tests and treatment profiling tests; and
- collaborating with pharmaceutical companies to launch re-profiling programmes on late-stage drug failures to gain regulatory approval on genetically-defined patient sub-groups.
By applying its expertise and proprietary technology to specific populations, Motif expects to make commercially-valuable discoveries on the genetic basis of diseases such as diabetes, asthma, and cancer and to develop the commercial value of these discoveries by partnering with pharmaceutical companies.
Amphion’s fully-diluted ownership stake in Motif was 43.14% as of 31 December 2009, valued at US $17.8 million (2008: US $15.4 million).
Management
Zaki Hosny - Chief Executive Officer
Dr. J. Claiborne Stephens - Chief Scientific Officer
Dr. Kevin Arnold - Executive Director, Industrial Genetics
Board of Directors
Richard C.E. Morgan - (Chairman) Chief Executive Officer, Amphion Innovations
Jon Gold - Senior Financial Analyst, Federated Investments
Gerard Moufflet - President and Chief Executive Officer, Acceleration International
Dr. Mary Lake Polan - Board of Directors, Wyeth Corporation, formally Professor and Chair emeritus, Department of Obstetrics and Gynecology, Stanford University School of Medicine
Dr. John Stakes - Director of Specialty Care Development, Harvard Medical School and Massachusetts General Hospital
Bruce Williams - Biotechnology Industry Consultant, formally held senior marketing positions at Celgene Corp., and Ortho Biotech, a Johnson & Johnson company
